Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SMPD4 (ImmuneEditome ID:55627)

1. Gene summary of enriched editing regions for SMPD4

Gene summary

Gene information	Gene symbol	SMPD4
	Gene ID	55627
	GeneSynonyms	NEDMABA\|NEDMEBA\|NET13\|NSMASE-3\|NSMASE3\|SKNY
	GeneCytomap	2q21.1
	GeneType	protein-coding
	GeneDescription	sphingomyelin phosphodiesterase 4\|neutral sphingomyelinase 3\|neutral sphingomyelinase III\|sphingomyelin phosphodiesterase 4, neutral membrane (neutral sphingomyelinase-3)
	GeneModificationdate	20230329
	UniprotID	Q9NXE4;F2Z2I0;F8WF03;F2Z2W5;A0A7P0Z453;H7C235;A0A7P0T9J6;A0A7P0TB24;A0A7P0TAZ0;A0A7P0TB44;H7C2E2;H7C0W5;C9J647;A0A7P0T8J0
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr2:130157849-130159654:-	ENST00000482171.4	ENSG00000136699.18	SMPD4	ncRNA_exonic	AluSz,AluJr,AluJb,AluSx	chr2:130157849-130159654:-.alignment
chr2:130167949-130168908:-	ENST00000473720.4	ENSG00000136699.18	SMPD4	ncRNA_intronic	AluJr,AluJb,AluJo,AluSz6	chr2:130167949-130168908:-.alignment

Top

2. Tumor-specific enriched editing regions for SMPD4

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr2:130157849-130159654:-	BRCA	EER	1.0700e-02
ENSG00000136699.18,SMPD4	BRCA	EAG	1.0877e-04

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000136699.18,SMPD4	ACC	Path	EAG	4.0741e-02	3.3030e-02	0.4665
chr2:130157849-130159654:-	UVM	Cli	EER	3.6775e-02	1.5804e-02	0.4971
ENSG00000136699.18,SMPD4	UVM	Cli	EAG	3.6775e-02	1.5804e-02	0.4971

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
ENSG00000136699.18,SMPD4	SARC	EAG	4.0925e-02	9.9179e-03	7.0762e-02

Top

3. Enriched editing regions and immune related genes for SMPD4

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr2:130157849-130159654:-

ESCA

EER

ENSG00000101216,GMEB2

-0.4841

4.2265e-06

2.4016e-08

-0.4336

Mast_cells_resting

GSVA_HALLMARK_G2M_CHECKPOINT

More results

Top

4. Enriched editing regions and immune related splicing for SMPD4

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000136699.18,SMPD4

ESCA

EAG

ENSG00000173933.15

chr11

66643749:66644140:66644633:66644743

-0.3907

3.2538e-03

7.2477e-07

-0.4004

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

Neutrophils

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr2:130157849-130159654:-

ESCA

EER

ENSG00000161547.10

chr17

76734122:76735875:76736153:76736464

-0.3529

1.9637e-02

1.4331e-07

-0.4111

T_cells_CD4_memory_resting

GSVA_HALLMARK_P53_PATHWAY

chr2:130157849-130159654:-

ESCA

EER

ENSG00000099917.13

chr22

20568980:20575232:20582610:20582747

-0.4071

2.1840e-03

8.6883e-08

-0.4176

T_cells_CD4_memory_resting

GSVA_HALLMARK_MTORC1_SIGNALING

ENSG00000136699.18,SMPD4

ESCA

EAG

ENSG00000161547.10

chr17

76734122:76735875:76736153:76736464

-0.3549

2.1821e-02

1.2156e-07

-0.4132

ACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_P53_PATHWAY

chr2:130157849-130159654:-

ESCA

EER

ENSG00000159086.10

chr21

32741392:32741622:32743247:32743268

-0.3059

2.0483e-02

7.2157e-06

-0.4032

T_cells_CD4_memory_resting

GSVA_HALLMARK_MYC_TARGETS_V1

chr2:130157849-130159654:-

ESCA

EER

ENSG00000173933.15

chr11

66643749:66644140:66644633:66644743

-0.3948

2.3647e-03

5.9409e-07

-0.4032

Neutrophils

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr2:130157849-130159654:-

ESCA

EER

ENSG00000168646.8

chr17

65536319:65536553:65537323:65537835:65536868:65537835

-0.2837

3.6186e-02

4.2857e-06

-0.4105

Macrophages_M0

GSVA_HALLMARK_BILE_ACID_METABOLISM

ENSG00000136699.18,SMPD4

ESCA

EAG

ENSG00000251322.3

chr22

50720183:50722437:50730720:50730737

-0.3907

3.6087e-03

3.1940e-07

-0.4042

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LARP7;LIN28;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;VIM;WTAP;YTHDC1;YTHDF1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr2:130157849-130159654:-

ESCA

EER

ENSG00000251322.3

chr22

50720183:50722437:50730720:50730737

-0.3951

2.6098e-03

2.5134e-07

-0.4074

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HEDGEHOG_SIGNALING

ENSG00000136699.18,SMPD4

ESCA

EAG

ENSG00000099917.13

chr22

20568980:20575232:20582610:20582747

-0.4033

2.9519e-03

9.6446e-08

-0.4162

ACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_MTORC1_SIGNALING

More results

Top

5. Enriched editing regions and immune infiltration for SMPD4

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr2:130157849-130159654:-	ACC	EER	T_cells_regulatory_(Tregs)	3.5962e-02	0.4712
ENSG00000136699.18,SMPD4	ACC	EAG	T_cells_regulatory_(Tregs)	3.0055e-02	0.4737
chr2:130157849-130159654:-	BLCA	EER	T_cells_CD4_memory_resting	2.1287e-02	-0.2224
ENSG00000136699.18,SMPD4	BLCA	EAG	Macrophages_M2	3.1293e-02	-0.2001
ENSG00000136699.18,SMPD4	BRCA	EAG	Dendritic_cells_activated	3.9102e-03	-0.1085
chr2:130157849-130159654:-	CESC	EER	Dendritic_cells_resting	3.7163e-02	0.1776
ENSG00000136699.18,SMPD4	CESC	EAG	Dendritic_cells_resting	1.2448e-02	0.2100
chr2:130157849-130159654:-	COAD	EER	T_cells_regulatory_(Tregs)	1.9654e-02	-0.2429
ENSG00000136699.18,SMPD4	COAD	EAG	T_cells_regulatory_(Tregs)	1.9778e-02	-0.2427
chr2:130157849-130159654:-	ESCA	EER	Dendritic_cells_resting	1.7612e-02	0.1923
ENSG00000136699.18,SMPD4	ESCA	EAG	Dendritic_cells_resting	1.7661e-02	0.1922
ENSG00000136699.18,SMPD4	GBM	EAG	T_cells_regulatory_(Tregs)	3.9059e-02	-0.2528
ENSG00000136699.18,SMPD4	HNSC	EAG	NK_cells_activated	2.4946e-02	-0.3078
ENSG00000136699.18,SMPD4	KIRC	EAG	T_cells_CD4_memory_resting	1.4168e-02	0.2147
chr2:130157849-130159654:-	LAML	EER	Macrophages_M0	3.2479e-02	0.1938
ENSG00000136699.18,SMPD4	LAML	EAG	Macrophages_M0	2.1854e-02	0.2075
chr2:130157849-130159654:-	LGG	EER	Macrophages_M1	1.5682e-02	0.1527
ENSG00000136699.18,SMPD4	LGG	EAG	Mast_cells_activated	1.2549e-03	-0.1990
chr2:130157849-130159654:-	LIHC	EER	Macrophages_M1	2.3694e-02	0.4422
chr2:130157849-130159654:-	LUAD	EER	T_cells_regulatory_(Tregs)	4.2594e-03	-0.1882
ENSG00000136699.18,SMPD4	LUAD	EAG	B_cells_naive	8.0414e-03	0.1700
chr2:130157849-130159654:-	LUSC	EER	Mast_cells_activated	2.9028e-02	0.1521
ENSG00000136699.18,SMPD4	LUSC	EAG	Mast_cells_activated	1.7899e-02	0.1625
ENSG00000136699.18,SMPD4	MESO	EAG	NK_cells_activated	9.2611e-03	-0.5414
ENSG00000136699.18,SMPD4	OV	EAG	NK_cells_resting	1.4111e-02	-0.1746
ENSG00000136699.18,SMPD4	PAAD	EAG	Mast_cells_activated	6.4215e-03	-0.3426
ENSG00000136699.18,SMPD4	PCPG	EAG	B_cells_naive	5.2285e-03	-0.2545
chr2:130157849-130159654:-	PRAD	EER	T_cells_CD4_memory_resting	1.8192e-02	0.1860
ENSG00000136699.18,SMPD4	PRAD	EAG	Macrophages_M2	2.4162e-02	-0.1760
chr2:130157849-130159654:-	READ	EER	T_cells_regulatory_(Tregs)	1.8600e-02	0.4137
ENSG00000136699.18,SMPD4	READ	EAG	T_cells_regulatory_(Tregs)	4.5241e-02	0.3509
chr2:130157849-130159654:-	SARC	EER	Eosinophils	1.8220e-04	0.4546
ENSG00000136699.18,SMPD4	SARC	EAG	Eosinophils	7.9085e-04	0.3868
chr2:130157849-130159654:-	SKCM	EER	Mast_cells_resting	2.9191e-02	0.1644
ENSG00000136699.18,SMPD4	SKCM	EAG	Dendritic_cells_resting	3.0836e-02	0.1597
chr2:130157849-130159654:-	STAD	EER	Dendritic_cells_resting	2.5970e-02	0.1488
ENSG00000136699.18,SMPD4	STAD	EAG	T_cells_regulatory_(Tregs)	8.0466e-03	0.1747
chr2:130157849-130159654:-	TGCT	EER	Neutrophils	1.7170e-02	-0.2579
ENSG00000136699.18,SMPD4	TGCT	EAG	Macrophages_M2	6.0200e-03	0.2890
chr2:130157849-130159654:-	THCA	EER	B_cells_naive	1.6199e-02	0.1598
ENSG00000136699.18,SMPD4	THCA	EAG	B_cells_naive	1.3466e-02	0.1635
chr2:130157849-130159654:-	THYM	EER	B_cells_naive	4.9758e-03	0.5338
ENSG00000136699.18,SMPD4	THYM	EAG	B_cells_naive	6.5375e-03	0.4934
ENSG00000136699.18,SMPD4	UCEC	EAG	T_cells_CD4_memory_resting	4.6875e-02	0.2401

Top

6. Enriched editing regions and immune gene sets for SMPD4

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr2:130157849-130159654:-	BRCA	EER	1.0123e-04	0.1490	3.4716e-02	0.0812	1.1123e-02	0.0976	2.7173e-03	0.1151

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000136699.18,SMPD4	ACC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.9785e-02	-0.4744
chr2:130157849-130159654:-	ACC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	4.3291e-02	-0.4560
chr2:130157849-130159654:-	BLCA	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	4.8716e-02	0.1910
ENSG00000136699.18,SMPD4	BLCA	GSVA_HALLMARK_COMPLEMENT	EAG	1.0018e-03	-0.3016
chr2:130157849-130159654:-	BRCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	2.1010e-04	0.1421
ENSG00000136699.18,SMPD4	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	7.6545e-06	-0.1675
chr2:130157849-130159654:-	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.6686e-03	-0.2395
ENSG00000136699.18,SMPD4	ESCA	GSVA_HALLMARK_HYPOXIA	EAG	3.3301e-03	0.2367
chr2:130157849-130159654:-	ESCA	GSVA_HALLMARK_HYPOXIA	EER	3.8249e-03	0.2333
chr2:130157849-130159654:-	HNSC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.0989e-02	0.3640
chr2:130157849-130159654:-	KIRP	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	2.3391e-02	0.2670
ENSG00000136699.18,SMPD4	KIRP	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	2.3391e-02	0.2670
ENSG00000136699.18,SMPD4	LAML	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	2.9969e-02	-0.1966
chr2:130157849-130159654:-	LAML	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	4.1146e-02	-0.1852
chr2:130157849-130159654:-	LGG	GSVA_HALLMARK_ADIPOGENESIS	EER	2.6878e-03	0.1891
ENSG00000136699.18,SMPD4	LGG	GSVA_HALLMARK_E2F_TARGETS	EAG	2.4442e-02	0.1395
ENSG00000136699.18,SMPD4	LIHC	GSVA_HALLMARK_COAGULATION	EAG	9.1744e-06	-0.5924
chr2:130157849-130159654:-	LIHC	GSVA_HALLMARK_P53_PATHWAY	EER	1.7986e-03	-0.5824
chr2:130157849-130159654:-	LUAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	3.4140e-02	0.1401
ENSG00000136699.18,SMPD4	LUAD	GSVA_HALLMARK_ADIPOGENESIS	EAG	1.6551e-03	-0.2012
chr2:130157849-130159654:-	LUSC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	2.1368e-02	0.1603
ENSG00000136699.18,SMPD4	MESO	GSVA_HALLMARK_E2F_TARGETS	EAG	3.3405e-02	0.4549
chr2:130157849-130159654:-	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	3.6297e-04	0.2567
ENSG00000136699.18,SMPD4	PAAD	GSVA_HALLMARK_ANGIOGENESIS	EAG	4.8982e-02	-0.2511
ENSG00000136699.18,SMPD4	PCPG	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	1.2232e-02	-0.2290
chr2:130157849-130159654:-	PRAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	4.5872e-02	-0.1576
ENSG00000136699.18,SMPD4	PRAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.4443e-02	-0.1907
ENSG00000136699.18,SMPD4	READ	GSVA_HALLMARK_APICAL_JUNCTION	EAG	5.4921e-03	-0.4725
chr2:130157849-130159654:-	READ	GSVA_HALLMARK_APICAL_JUNCTION	EER	1.1246e-03	-0.5495
ENSG00000136699.18,SMPD4	SARC	GSVA_HALLMARK_COAGULATION	EAG	2.9164e-03	-0.3459
ENSG00000136699.18,SMPD4	SKCM	GSVA_HALLMARK_MYOGENESIS	EAG	1.1442e-02	-0.1866
chr2:130157849-130159654:-	SKCM	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.7652e-02	0.1787
ENSG00000136699.18,SMPD4	STAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	4.7792e-02	0.1309
chr2:130157849-130159654:-	STAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	1.2670e-02	0.1663
chr2:130157849-130159654:-	TGCT	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.0656e-03	-0.3086
ENSG00000136699.18,SMPD4	TGCT	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	5.8425e-03	0.2900
chr2:130157849-130159654:-	THCA	GSVA_HALLMARK_E2F_TARGETS	EER	1.4300e-02	0.1628
ENSG00000136699.18,SMPD4	THCA	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.1186e-02	0.1677
chr2:130157849-130159654:-	THYM	GSVA_HALLMARK_UV_RESPONSE_DN	EER	3.4822e-02	-0.4154
ENSG00000136699.18,SMPD4	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.3673e-02	-0.2956
chr2:130157849-130159654:-	UVM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	2.8077e-02	0.4577
ENSG00000136699.18,SMPD4	UVM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	2.8077e-02	0.4577

Top

7. Enriched editing regions and drugs for SMPD4

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr2:130157849-130159654:-	ACC	Elesclomol	EER	4.2013e-02	-0.4585
ENSG00000136699.18,SMPD4	ACC	Elesclomol	EAG	4.7854e-02	-0.4366
ENSG00000136699.18,SMPD4	BLCA	BMS.536924	EAG	2.7273e-03	0.2758
chr2:130157849-130159654:-	BLCA	AS601245	EER	2.0539e-02	0.2237
chr2:130157849-130159654:-	BRCA	CCT007093	EER	5.5413e-03	0.1066
ENSG00000136699.18,SMPD4	BRCA	Axitinib	EAG	4.4096e-05	-0.1532
chr2:130157849-130159654:-	CESC	Docetaxel	EER	2.8289e-02	-0.1867
chr2:130157849-130159654:-	ESCA	Bleomycin	EER	3.1530e-03	-0.2380
ENSG00000136699.18,SMPD4	ESCA	Bleomycin	EAG	3.2075e-03	-0.2376
ENSG00000136699.18,SMPD4	GBM	EHT.1864	EAG	3.4284e-02	0.2590
chr2:130157849-130159654:-	GBM	CGP.60474	EER	3.9230e-02	-0.2544
chr2:130157849-130159654:-	HNSC	Gemcitabine	EER	4.6362e-03	0.4019
ENSG00000136699.18,SMPD4	HNSC	AKT.inhibitor.VIII	EAG	1.2845e-02	-0.3396
chr2:130157849-130159654:-	KIRC	Lapatinib	EER	3.7992e-02	0.1829
ENSG00000136699.18,SMPD4	KIRC	Metformin	EAG	2.4284e-02	0.1975
ENSG00000136699.18,SMPD4	KIRP	AZD6482	EAG	3.0285e-02	0.2555
chr2:130157849-130159654:-	KIRP	AZD6482	EER	3.0285e-02	0.2555
ENSG00000136699.18,SMPD4	LAML	LFM.A13	EAG	7.2716e-03	-0.2419
chr2:130157849-130159654:-	LAML	LFM.A13	EER	2.4336e-02	-0.2038
ENSG00000136699.18,SMPD4	LGG	Dasatinib	EAG	1.0733e-02	-0.1580
chr2:130157849-130159654:-	LGG	GNF.2	EER	2.0715e-03	-0.1939
ENSG00000136699.18,SMPD4	LIHC	GSK.650394	EAG	9.6203e-07	-0.6401
chr2:130157849-130159654:-	LIHC	JW.7.52.1	EER	5.3200e-03	0.5303
ENSG00000136699.18,SMPD4	LUAD	GNF.2	EAG	1.4811e-04	0.2415
chr2:130157849-130159654:-	LUAD	GNF.2	EER	4.2538e-03	0.1882
ENSG00000136699.18,SMPD4	LUSC	BIBW2992	EAG	2.3153e-03	-0.2082
chr2:130157849-130159654:-	LUSC	BIBW2992	EER	8.5289e-03	-0.1828
ENSG00000136699.18,SMPD4	MESO	Lapatinib	EAG	8.1404e-03	0.5490
ENSG00000136699.18,SMPD4	OV	JNK.Inhibitor.VIII	EAG	1.2719e-03	0.2280
chr2:130157849-130159654:-	OV	CCT007093	EER	6.4154e-05	0.2865
chr2:130157849-130159654:-	PAAD	BI.D1870	EER	2.5664e-02	0.2929
chr2:130157849-130159654:-	PCPG	IPA.3	EER	3.6234e-02	0.2097
ENSG00000136699.18,SMPD4	PCPG	Bosutinib	EAG	6.0881e-03	-0.2501
ENSG00000136699.18,SMPD4	PRAD	MG.132	EAG	2.2814e-03	0.2366
chr2:130157849-130159654:-	PRAD	MG.132	EER	1.7887e-03	0.2443
chr2:130157849-130159654:-	READ	AZD.0530	EER	3.3237e-02	0.3774
ENSG00000136699.18,SMPD4	READ	Cytarabine	EAG	2.5337e-02	-0.3888
chr2:130157849-130159654:-	SARC	BIBW2992	EER	8.1081e-03	-0.3307
ENSG00000136699.18,SMPD4	SARC	Bexarotene	EAG	1.0872e-03	0.3773
ENSG00000136699.18,SMPD4	SKCM	A.443654	EAG	2.6625e-03	0.2208
chr2:130157849-130159654:-	SKCM	A.443654	EER	5.5251e-03	0.2083
ENSG00000136699.18,SMPD4	STAD	GW843682X	EAG	1.0330e-02	-0.1692
chr2:130157849-130159654:-	STAD	BAY.61.3606	EER	9.5037e-03	0.1729
ENSG00000136699.18,SMPD4	TGCT	IPA.3	EAG	1.2651e-03	0.3365
chr2:130157849-130159654:-	TGCT	MG.132	EER	5.0899e-03	-0.3012
ENSG00000136699.18,SMPD4	THCA	BAY.61.3606	EAG	8.0052e-03	-0.1752
chr2:130157849-130159654:-	THYM	AICAR	EER	1.1811e-02	-0.4861
ENSG00000136699.18,SMPD4	THYM	Methotrexate	EAG	1.3479e-02	-0.4535
ENSG00000136699.18,SMPD4	UCEC	Camptothecin	EAG	5.3166e-03	0.3320
chr2:130157849-130159654:-	UCEC	Camptothecin	EER	2.4668e-02	0.2807
chr2:130157849-130159654:-	UVM	CHIR.99021	EER	2.2395e-02	0.4738
ENSG00000136699.18,SMPD4	UVM	CHIR.99021	EAG	2.2395e-02	0.4738

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType